Interactions of laminin with the amyloid β peptide. Implications for Alzheimer’s disease

C. Morgan and N.C. Inestrosa

Abstract

Extensive neuronal cell loss is observed in Alzheimer’s disease. Laminin immunoreactivity colocalizes with senile plaques, the characteristic extracellular histopathological lesions of Alzheimer brain, which consist of the amyloid β (Aβ) peptide polymerized into amyloid fibrils. These lesions have neurotoxic effects and have been proposed to be a main cause of neurodegeneration. In order to understand the pathological significance of the interaction between laminin and amyloid, we investigated the effect of laminin on amyloid structure and toxicity. We found that laminin interacts with the Aβ1-40 peptide, blocking fibril formation and even inducing depolymerization of preformed fibrils. Protofilaments known to be intermediate species of Aβ fibril formation were also detected as intermediate species of laminin-induced Aβ fibril depolymerization. Moreover, laminin-amyloid interactions inhibited the toxic effects on rat primary hippocampal neurons. As a whole, our results indicate a putative anti-amyloidogenic role of laminin which may be of biological and therapeutic interest for controlling amyloidosis, such as those observed in cerebral angiopathy and Alzheimer’s disease.

Key words
- Extracellular matrix
- Laminin
- Amyloid β peptide
- Neuronal injury
- Neurodegenerative disease

Introduction

Laminin is a major basement membrane glycoprotein (M~850 kDa) widely distributed in the extracellular matrix (ECM). At least 11 isoforms of laminin have been described due to the presence of five different α chains (α1-α5) of 200-400 kDa which combine with β (220 kDa) and γ (210 kDa) chains into disulfide-bonded heterotrimers arranged in a cross-shaped structure (1,2). These three chains are coded by different genes (3-5). The C-terminal globular domains of the α chain are critical for appropriate assembly of the whole glycoprotein (6). This region is also important for driving laminin polymerization and heparin binding (7,8). Several other ECM proteins may bind laminin through these globular domains, such as perlecan, α-dystroglycan, fibulin-1, fibulin-2, and nidogen-2 (9,10). Because of its large size, complexity and multidomain nature, laminin exhibits a variety of functions still not completely understood, namely the ability of laminin to keep the ECM assembled, to promote neurite outgrowth, growth cone guidance, pathfinding, and synapse formation (11,12).

The importance of amyloid β peptide in Alzheimer’s disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized...
by a loss of memory which finally determines the clinical onset of dementia. Alzheimer brains are histopathologically characterized by numerous senile plaques and neurofibrillary tangles. Both lesions are considered to be of pivotal importance to understand AD. In addition, genetic evidence points at the regulation of amyloid precursor protein (APP) metabolism as a key factor in the pathogenesis of AD (13). Amyloid-derived neurotoxicity is widely considered as a main factor explaining the neurodegenerative changes observed in AD. The neurotoxic effect of amyloid β (Aβ) peptide, a proteolytic fragment of APP, is associated with its polymerization state as amyloid fibrils (14,15). Studies of amyloid-derived neurotoxicity in vivo have shown an increased vulnerability to neurotoxicity with aging (16), suggesting the participation of some age-dependent factors.

**ECM components and APP**

Because of the extracellular deposition of Aβ peptide in senile plaques, particular attention has been paid to interactions between amyloid and ECM components (17). Indeed, several basement membrane components such as heparan sulfate proteoglycans, type IV collagen and laminin have been found in senile plaques (18). Moreover, proteoglycans and laminin interact with APP (19-21) and these interactions seem to disrupt the normal associations among ECM components (22), suggesting that an over-production of APP may change the normal functions of ECM. On the other hand, APP metabolism is affected by ECM components both in microglial (23) and neuronal (24) cell types.

**The anti-amyloidogenic role of laminin**

Laminin immunoreactivity is observed mainly associated with blood vessels and reactive astrocytes in normal brains but also in neuronal cell bodies in most parts of the developing and adult rat central nervous system (25). Its expression seems to be increased after brain injury (26) and in the brain of AD and Down syndrome patients (27). In order to examine the pathological significance of laminin induction in Alzheimer brains, we studied the effect of laminin on Aβ peptide polymerization, and we showed for the first time that laminin was a
potent inhibitor of Aβ fibril formation (28,29). Figure 1A shows a turbidity assay indicating that Aβ aggregation in the presence of laminin was clearly decreased, and that the formation of amyloid was also diminished in the presence of laminin, as evidenced by Congo red staining (Figure 1B). These observations confirm those obtained by other authors (30,31). Since an inhibition of fibril formation is expected to be accompanied by an attenuation of amyloid neurotoxicity, we have proposed that laminin may have a therapeutic potential in the treatment of AD. In fact, a diminished neurotoxicity of amyloid has been observed in the presence of laminin in rat primary hippocampal neurons (Figure 2). Similar results have been observed in primary cortical cells (32).

Since a kinetic inhibition of amyloidogenesis may retard but not reverse Aβ fibril formation, we decided to investigate the ability of laminin to depolymerize preformed Aβ fibrils (33). The studies were carried out using molar ratios of Aβ to laminin-1 of 2,500 or less. Amyloid depolymerization induced by laminin is a concentration- and time-dependent reaction (Figure 3A) characterized by the appearance of protofilaments at the expenses of preformed fibrils, which finally leads to their clearance, forming amorphous non-amyloid material, as observed by electron microscopy examination (Figure 3B). These observations suggest that laminin behaves as a thermodynamic inhibitor of amyloidogenesis. But if so, why does amyloidosis proceed in Alzheimer brains? Several answers are possible, including one that may involve laminin degradation. In fact, it has been shown that plasmin-catalyzed degradation of laminin mediates neuronal death in the hippocampus after excitotoxic injury with kainate (34). In that study, the authors demonstrated that disruption of laminin-neuron interaction makes neurons sensitive to excitotoxic death. Therefore, it is reasonable to assume that the interaction of laminin with the Aβ peptide may disrupt normal interactions with cells. Moreover, we have recently found that several laminin-derived peptides, including the IKVAV sequence (neurite promotor activity; 21), inhibit amyloidogenesis. The efficacy of laminin in depolymerizing Aβ suggests that this glyco-
protein may exhibit a number of active sequences interacting with amyloid. This may involve the loss of several normal functions of laminin including its role in the survival of neurons.

**Therapeutic potential of laminin in Alzheimer’s disease**

The anti-amyloidogenic properties of laminin make it suitable for therapeutic use; however, several points have to be considered. First, the interactions between laminin and amyloid may disrupt normal functions of laminin including its role in neuronal survival. Therefore, it is important to determine which laminin regions are involved in this anti-amyloidogenic activity in order to synthesize defined laminin-derived peptides or peptidomimetics. Second, such peptides have to cross the blood-brain barrier and find their appropriate target regions in the brain. This problem may not be difficult to solve considering that pentapeptides disrupting the amyloid fibril structure and satisfying this property have already been designed (35).

**References**


